Home Cart 0 Sign in  
X

[ CAS No. 381233-78-9 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
3d Animation Molecule Structure of 381233-78-9
Chemical Structure| 381233-78-9
Chemical Structure| 381233-78-9
Structure of 381233-78-9 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 381233-78-9 ]

Related Doc. of [ 381233-78-9 ]

Alternatived Products of [ 381233-78-9 ]

Product Details of [ 381233-78-9 ]

CAS No. :381233-78-9 MDL No. :MFCD11113414
Formula : C10H8N2O Boiling Point : -
Linear Structure Formula :- InChI Key :NHWKTZWOSIVHOL-UHFFFAOYSA-N
M.W : 172.18 Pubchem ID :10241257
Synonyms :

Calculated chemistry of [ 381233-78-9 ]

Physicochemical Properties

Num. heavy atoms : 13
Num. arom. heavy atoms : 12
Fraction Csp3 : 0.0
Num. rotatable bonds : 1
Num. H-bond acceptors : 2.0
Num. H-bond donors : 1.0
Molar Refractivity : 50.29
TPSA : 45.75 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : Yes
P-gp substrate : No
CYP1A2 inhibitor : Yes
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -7.1 cm/s

Lipophilicity

Log Po/w (iLOGP) : 1.57
Log Po/w (XLOGP3) : 0.35
Log Po/w (WLOGP) : 1.44
Log Po/w (MLOGP) : 0.76
Log Po/w (SILICOS-IT) : 2.63
Consensus Log Po/w : 1.35

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 1.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -1.75
Solubility : 3.1 mg/ml ; 0.018 mol/l
Class : Very soluble
Log S (Ali) : -0.88
Solubility : 23.0 mg/ml ; 0.133 mol/l
Class : Very soluble
Log S (SILICOS-IT) : -4.07
Solubility : 0.0146 mg/ml ; 0.0000847 mol/l
Class : Moderately soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 0.0 alert
Leadlikeness : 1.0
Synthetic accessibility : 2.31

Safety of [ 381233-78-9 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P261-P305+P351+P338 UN#:N/A
Hazard Statements:H302-H315-H319-H335 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 381233-78-9 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 381233-78-9 ]
  • Downstream synthetic route of [ 381233-78-9 ]

[ 381233-78-9 ] Synthesis Path-Upstream   1~17

  • 1
  • [ 381233-78-9 ]
  • [ 380917-97-5 ]
Reference: [1] Synthesis, 2012, vol. 44, # 1, p. 57 - 62
[2] Journal of Medicinal Chemistry, 2012, vol. 55, # 23, p. 10584 - 10600
[3] Patent: US2016/39759, 2016, A1,
[4] Patent: WO2016/147104, 2016, A1,
  • 2
  • [ 109-04-6 ]
  • [ 1054483-78-1 ]
  • [ 381233-78-9 ]
YieldReaction ConditionsOperation in experiment
70% With tetrakis(triphenylphosphine) palladium(0); sodium carbonate In water; acetonitrile at 75℃; Finally, several additional analogues designed to evaluate replacement of the pyridazine in 1 with phenyl and pyridyl moieties, were prepared using the methodology outlined in Scheme 3. Suzuki coupling of 2-bromopyridine (18) with various boronic acids afforded 19 and 20 (Ghiron et al, J. Med. Chem. 2010, 53, 4379). Treatment of 20 with P2S5 in pyridine at 120 °C provided 21 in 71percent yield. Alkylation of 21 with 2- methylbenzyl bromide in the presence of K2C03 in DMF generated 22. Scheme 3. Reagents and conditions: (a) Pd(PPh3)4, Na2C03, CH3CN/H20 (1/1), 75 °C, 4- benzylthiophenylboronic acid (54percent); (b) Pd(PPh3)4, Na2C03, CH3CN/H20 (1/1), 75 °C, 6-hydroxypyridine-3-boronic acid pinacol ester (70percent>); (c) P2S5, pyridine, 120 °C (71percent>); (d) 2-methylbenzyl bromide, K2C03, DMF (76percent).
Reference: [1] Bioorganic and Medicinal Chemistry Letters, 2011, vol. 21, # 19, p. 5774 - 5777
[2] Patent: WO2013/19938, 2013, A1, . Location in patent: Page/Page column 34; 35
  • 3
  • [ 381725-49-1 ]
  • [ 381233-78-9 ]
YieldReaction ConditionsOperation in experiment
80.9% at 95 - 100℃; for 4 h; Acidic conditions The acid aqueous phase containing 2-methoxy-5-(pyridin-2-yl)pyridine obtained according to Example 3 is reintroduced into the reactor C. The mixture is heated to reflux (95-100°C) for at least 4 h. The conversion is monitored in HPLC. When the reaction is complete, it is cooled to 20-25°C, the acid aqueous phase is washed with 3.54 L (5.9 V) of MTBE (the product is in aqueous phase). Stirring is continued for 15 min, the mixture is left to decant and the phases are separated. Once the phases are separated, the pH of the aqueous phase (containing the product) is adjusted to 12.5-13 with approximately 1.5 L of sodium hydroxide 30percent solution. The basic aqueous phase so obtained is washed with 3.54 L (5.9 V) of MTBE (the product is in aqueous phase). Stirring is continued for 15 min, the mixture is left to decant and the phases are separated. The pH of the aqueous phase is adjusted to about 7-7.5 with approximately 0.3 L of concentrated hydrochloric acid. 7.26 L (12.1 V) of n-butanol and a solution of sodium chloride at 20percent, obtained by mixing 0.67 kg (1 . 12 W) of sodium chloride and 2.68 1 (4.47 V) of purified water, are added to the aqueous phase. Stirring is continued for 15 min, the mixture is left to decant and the phases are separated (the product passes into the organic phase). The aqueous phase is again extracted with 7.26 L (12.1 V) of n-butanol. Stirring is continued for 15 min, the mixture is left to decant and the phases are separated. The organic phase so obtained are evaporated at 45-60°C under vacuum to a residue. The distillation residue is recovered with 2.4 L (4 V) of ethyl acetate. The mixture is heated to reflux and stirred for 15 min. It is cooled to 20-25 °C and stirred 30 min and then it is cooled to -10/-5°C and stirred for at least 2 h. The mixture is filtered and washed with 2x0.60 L (2x1 V) of cold ethyl acetate (-10/-5 °C). The product is dried at 45-50 °C under vacuum for at least 6 h. 736 g of product are obtained, equal to a molar yield of 80.9percent from starting 2-chloro-pyridine (HPLC purity A/Apercent 99.40).
80.9% With hydrogenchloride In water at 80 - 100℃; for 4 h; General procedure: The acid aqueous phase containing 2-methoxy-5-(pyridin-2-yl)pyridine obtained according to Example 3 was reintroduced into the reactor C. The mixture was heated to reflux (95-100° C.) for at least 4 h. The conversion was monitored in HPLC. When the reaction was complete, it was cooled to 20-25° C., the acid aqueous phase was washed with 3.54 L (5.9 V) of MTBE (the product was in aqueous phase). Stirring was continued for 15 min, the mixture was left to decant and the phases were separated. Once the phases were separated, the pH of the aqueous phase (containing the product) was adjusted to 12.5-13 with approximately 1.5 L of   sodium hydroxide 30percent solution. The basic aqueous phase so obtained was washed with 3.54 L (5.9 V) of MTBE (the product was in aqueous phase). Stirring was continued for 15 min, the mixture was left to decant and the phases were separated. The pH of the aqueous phase was adjusted to about 7-7.5 with approximately 0.3 L of   concentrated hydrochloric acid. 7.26 L (12.1 V) of   n-butanol and a solution of   sodium chloride at 20percent, obtained by mixing 0.67 kg (1.12 W) of sodium chloride and 2.68 l (4.47 V) of purified   water, were added to the aqueous phase. Stirring was continued for 15 min, the mixture was left to decant and the phases were separated (the product passed into the organic phase). The aqueous phase was again extracted with 7.26 L (12.1 V) of n-butanol. Stirring was continued for 15 min, the mixture was left to decant and the phases were separated. The organic phase so obtained were evaporated at 45-60° C. under vacuum to a residue. The distillation residue was recovered with 2.4 L (4 V) of   ethyl acetate. The mixture was heated to reflux and stirred for 15 min. It was cooled to 20-25° C. and stirred 30 min and then it was cooled to −10/−5° C. and stirred for at least 2 h. The mixture was filtered and washed with 2×0.60 L (2×1 V) of cold ethyl acetate (−10-5° C.). The product was dried at 45-50° C. under vacuum for at least 6 h. 736 g of   product were obtained, equal to a molar yield of 80.9percent from starting 2-chloro-pyridine (HPLC purity A/A percent 99.4percent).
60% With hydrogenchloride In water for 4 h; Heating / reflux Crude 6-methoxy-3,2'-bipyridine (55.0 kg, net: 42.6 kg) obtained in Example 2, 35percent hydrochloric acid (65 kg) and water (110 kg) were charged in a reactor vessel (inner volume 500 L) and the mixture was heated under reflux for 4 hr. The reaction mixture was cooled and the aqueous layer was washed with methyl-tert-butyl ether (116 kgx4). A solution obtained by dissolving sodium hydroxide (35 kg) in water (102 kg) was added while maintaining the inside temperature at 25-35C to adjust its pH to 12, and the aqueous layer was washed again with methyl-tert-butyl ether (116 kg?2). 35percent Hydrochloric acid (40 kg) was added while maintaining the inside temperature at 25-40C to adjust its pH to 7. This mixture was transferred to a reactor vessel (inner volume 1000 L), n-butanol (175 kg) was added and sodium chloride (70 kg) was further added. The organic layer was separated and the aqueous layer was extracted with n-butanol (175 kg). The extract and the organic layer were combined and concentrated until n-butanol remaining in the reactor vessel became 69 kg. Ethyl acetate (84 kg) was added to the concentrate, and the mixture was dissolved by heating to 80C and cooled to 0C to allow recrystallization to give crude 5-(2'-pyridyl)-2-pyridone (32.1 kg, net: 29.1 kg). This was added to water (224 kg), dissolved by heating to 60C and cooled to 0C. The obtained slurry was filtered, washed with water (45 kg) and dried to give 5-(2'-pyridyl)-2-pyridone (23.56 kg, yield 60percent).1H-NMR spectrum (CDCl3) ?: 6.72(d,1H,J=9.9Hz), 7.19(dd,1H,J=4.9Hz,6.9Hz), 7.51(d,1H,J=7.9Hz), 7.70-7.76(m,1H), 8.15-8.23 (m,2H), 8.62(d,1H,J=4.0Hz), 13.30(brs, 1H)
Reference: [1] Patent: EP2586777, 2013, A1, . Location in patent: Paragraph 0064
[2] Patent: US2013/109862, 2013, A1, . Location in patent: Paragraph 0084
[3] Journal of Medicinal Chemistry, 2012, vol. 55, # 23, p. 10584 - 10600
[4] Patent: EP1553086, 2005, A1, . Location in patent: Page/Page column 8
[5] Patent: EP2123639, 2009, A1, . Location in patent: Page/Page column 17
[6] Synthesis, 2012, vol. 44, # 1, p. 57 - 62
  • 4
  • [ 13472-85-0 ]
  • [ 197958-29-5 ]
  • [ 381233-78-9 ]
Reference: [1] Patent: US2016/39759, 2016, A1, . Location in patent: Paragraph 0057-0058
  • 5
  • [ 342618-54-6 ]
  • [ 381233-78-9 ]
YieldReaction ConditionsOperation in experiment
57.8%
Stage #1: With hydrogenchloride; water In toluene at 100℃; for 10 h;
Stage #2: With potassium carbonate In water
Examples 37 to 41: 2,3'-Bipyridyl-6'-one was synthesized by the same operation as in Example 1 and Example 23 except for using the nicotinic acid derivative shown in Table 4. In Example 37, 2,3'-bipyridyl-6'-one could be directly synthesized and therefore, the operation of hydrolysis in Example 23 was omitted.
Reference: [1] Patent: EP2123639, 2009, A1, . Location in patent: Page/Page column 17
  • 6
  • [ 93297-75-7 ]
  • [ 381233-78-9 ]
Reference: [1] Patent: EP2123639, 2009, A1, . Location in patent: Page/Page column 15
[2] Patent: US2010/16603, 2010, A1, . Location in patent: Page/Page column 11
[3] Patent: CN104356056, 2017, B, . Location in patent: Paragraph 0049-0050
  • 7
  • [ 1124-29-4 ]
  • [ 21966-78-9 ]
  • [ 381233-78-9 ]
Reference: [1] Patent: EP2123639, 2009, A1, . Location in patent: Page/Page column 17
  • 8
  • [ 381725-49-1 ]
  • [ 71-36-3 ]
  • [ 381233-78-9 ]
  • [ 28509-24-2 ]
Reference: [1] Patent: EP1300396, 2003, A1,
  • 9
  • [ 109-04-6 ]
  • [ 163105-89-3 ]
  • [ 381233-78-9 ]
Reference: [1] Journal of Medicinal Chemistry, 2015, vol. 58, # 21, p. 8444 - 8462
  • 10
  • [ 624-28-2 ]
  • [ 381233-78-9 ]
Reference: [1] Synthesis, 2012, vol. 44, # 1, p. 57 - 62
[2] Journal of Medicinal Chemistry, 2012, vol. 55, # 23, p. 10584 - 10600
  • 11
  • [ 13472-85-0 ]
  • [ 381233-78-9 ]
Reference: [1] Synthesis, 2012, vol. 44, # 1, p. 57 - 62
[2] Journal of Medicinal Chemistry, 2012, vol. 55, # 23, p. 10584 - 10600
  • 12
  • [ 17997-47-6 ]
  • [ 381233-78-9 ]
Reference: [1] Synthesis, 2012, vol. 44, # 1, p. 57 - 62
  • 13
  • [ 163105-89-3 ]
  • [ 381233-78-9 ]
Reference: [1] Journal of Medicinal Chemistry, 2012, vol. 55, # 23, p. 10584 - 10600
  • 14
  • [ 58757-38-3 ]
  • [ 381233-78-9 ]
Reference: [1] Patent: CN104356056, 2017, B,
  • 15
  • [ 5326-23-8 ]
  • [ 381233-78-9 ]
Reference: [1] Patent: CN104356056, 2017, B,
  • 16
  • [ 149281-42-5 ]
  • [ 381233-78-9 ]
Reference: [1] Patent: CN104356056, 2017, B,
  • 17
  • [ 381233-78-9 ]
  • [ 381248-06-2 ]
Reference: [1] Synthesis, 2012, vol. 44, # 1, p. 57 - 62
[2] Journal of Medicinal Chemistry, 2012, vol. 55, # 23, p. 10584 - 10600
[3] Patent: US2016/39759, 2016, A1,
[4] Patent: WO2016/147104, 2016, A1,
Same Skeleton Products
Historical Records

Pharmaceutical Intermediates of
[ 381233-78-9 ]

Perampanel Intermediates

Chemical Structure| 624-28-2

[ 624-28-2 ]

2,5-Dibromopyridine

Chemical Structure| 381248-06-2

[ 381248-06-2 ]

3-Bromo-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one

Chemical Structure| 381233-96-1

[ 381233-96-1 ]

5-Bromo-3-iodopyridin-2-amine

Chemical Structure| 16179-97-8

[ 16179-97-8 ]

2-(Pyridin-2-yl)acetic acid hydrochloride

Chemical Structure| 1072-97-5

[ 1072-97-5 ]

5-Bromopyridin-2-amine

Related Functional Groups of
[ 381233-78-9 ]

Amides

Chemical Structure| 23616-31-1

[ 23616-31-1 ]

1,6-Naphthyridin-5(6H)-one

Similarity: 0.87

Chemical Structure| 22433-76-7

[ 22433-76-7 ]

N-(Quinolin-6-yl)acetamide

Similarity: 0.86

Chemical Structure| 67967-11-7

[ 67967-11-7 ]

1,7-Naphthyridin-8(7H)-one

Similarity: 0.79

Chemical Structure| 155058-02-9

[ 155058-02-9 ]

7,8-Dihydro-1,6-naphthyridin-5(6H)-one

Similarity: 0.79

Chemical Structure| 91025-05-7

[ 91025-05-7 ]

N-(2-Picolinoylphenyl)benzamide

Similarity: 0.74

Related Parent Nucleus of
[ 381233-78-9 ]

Pyridines

Chemical Structure| 127406-56-8

[ 127406-56-8 ]

4-(Pyridin-2-yl)benzaldehyde

Similarity: 0.77

Chemical Structure| 91025-05-7

[ 91025-05-7 ]

N-(2-Picolinoylphenyl)benzamide

Similarity: 0.74

Chemical Structure| 58539-65-4

[ 58539-65-4 ]

2-Methylnicotinamide

Similarity: 0.73

Chemical Structure| 80047-24-1

[ 80047-24-1 ]

2-Methyl-6-oxo-1,6-dihydro-[3,4'-bipyridine]-5-carboxamide

Similarity: 0.73

Chemical Structure| 3034-31-9

[ 3034-31-9 ]

N-Phenyl isonicotinicamide

Similarity: 0.72